Literature DB >> 6427485

Endocrine dysfunction in impotence: incidence, significance and cost-effective screening.

J C Nickel, A Morales, M Condra, J Fenemore, D H Surridge.   

Abstract

A comprehensive evaluation of impotence includes assessment of the functional integrity of the hypothalamic-pituitary-gonadal axis. However, little is known about the incidence or significance of hormonal abnormalities in an unselected group of men with erectile failure. A systematic multidisciplinary, multidimensional assessment of 256 impotent men showed clearly an organic etiology in 35.9 per cent, psychogenic in 38.3 per cent and mixed or uncertain in 25.8 per cent. The incidence of hypothalamic-pituitary-gonadal axis abnormalities in the entire group was 17.5 per cent but in only 12.1 per cent did they contribute clearly to erectile dysfunction. A cost-effective screening of the endocrine system in impotent men includes a thorough history and physical examination, and a serum testosterone determination. More sophisticated and expensive investigations should be reserved for patients with a history of drug use known to induce hormonal abnormalities or with somatic evidence of hypogonadism and a depressed serum testosterone level.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6427485     DOI: 10.1016/s0022-5347(17)49454-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  The role of routine serum testosterone testing: routine hormone analysis is not indicated as an initial screening test in the evaluation of erectile dysfunction.

Authors:  Gregory Jack; Scott I Zeitlin
Journal:  Rev Urol       Date:  2004

2.  "Organic" erection dysfunction: diagnosis and treatment.

Authors:  R W Stevenson
Journal:  Can Fam Physician       Date:  1988-08       Impact factor: 3.275

3.  Evaluation of impotence.

Authors:  M Cooke
Journal:  West J Med       Date:  1986-07

4.  Multicentral clinical evaluation of the aetiology of erectile dysfunction: a survey report.

Authors:  S Aydin; D Unal; H Erol; I Karaman; Y Yilmaz; E Sengül; H Bayrakli
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

5.  Hyperprolactinemia and erectile dysfunction.

Authors:  S I Zeitlin; J Rajfer
Journal:  Rev Urol       Date:  2000

6.  The role of serum testosterone testing: routine hormone analysis is an essential part of the initial screening of men with erectile dysfunction.

Authors:  John Gore; Jacob Rajfer
Journal:  Rev Urol       Date:  2004

Review 7.  Erectile dysfunction: management update.

Authors:  Luke Fazio; Gerald Brock
Journal:  CMAJ       Date:  2004-04-27       Impact factor: 8.262

Review 8.  Which patients with sexual dysfunction are suitable for testosterone replacement therapy?

Authors:  A Morelli; G Corona; S Filippi; S Ambrosini; G Forti; L Vignozzi; M Maggi
Journal:  J Endocrinol Invest       Date:  2007-11       Impact factor: 4.256

Review 9.  Androgen therapy in the aging male.

Authors:  Bruno Lunenfeld
Journal:  World J Urol       Date:  2003-10-24       Impact factor: 4.226

10.  Does regular consumption of green tea influence expression of vascular endothelial growth factor and its receptor in aged rat erectile tissue? Possible implications for vasculogenic erectile dysfunction progression.

Authors:  D Neves; M Assunção; F Marques; J P Andrade; H Almeida
Journal:  Age (Dordr)       Date:  2008-04-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.